New Data from SLN124 Healthy Volunteer Study Reinforce Broad Therapeutic Potential in Hematological Diseases Data presented at 2021 ASH annual...
-- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS...
U.K. regulatory authorities grant Clinical Trial Authorization with dosing of first patient anticipated in the first half of 2022 NX‑5948...
Real-world experience study of more than 3,100 patients demonstrates statistically significant reductions in transfusions, vaso-occlusive crises and hospitalizations in patients...
Premier bilan partiel de 1 300 000 $ recueillis, en date du 11 décembre 2021 Guignolée Dr Julien 11 décembre...
Oral poster presentation highlights data from dose-escalation trial of allogeneic CD30.CAR EBVST cell therapy (TT11X) in patients with relapsed or...
– Poster presentation highlights NL-201 activity in multiple myeloma stem cell transplant model – – Abstract reports activity of NL-201 as monotherapy...
Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs....
VIP152 has increased selectivity and potency compared to other CDK9 inhibitors in development, consistent across DLBCL and CLL models of...
- Data Presented Shows Novel Bispecific IgM Antibody is Active in Heavily Pre-treated Patients with Relapsed/Refractory NHL, including DLBCL and...
Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant...
Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab (FCA) with no Dose-Limiting Toxicities in...
Press release Hørsholm, Denmark (December 11, 2021) — Allarity Therapeutics A/S (“Allarity A/S” or the “Company”) today announced that...
